Burkitt Lymphoma · line 2 · R-DHAP (Rituximab + Dexamethasone + HD-Cytarabine + Cisplatin) × 2-3 cycles → ASCT/alloSCT (r/r Burkitt salvage; non-cross-resistant alternative to R-ICE)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-RDHAP-BURKITT |
| ID | IND-BURKITT-2L-RDHAP-ASCT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-BURKITT |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ alternative to R-ICE for r/r Burkitt. CNS disease at relapse favors R-DHAP. ASCT consolidation in CR2 is goal.
Used By
Algorithms
ALGO-BURKITT-2L- ALGO-BURKITT-2L